Michael Winter 1 , Dirk Boecker 2 and Wilfried Posch 3,*
1 Team Winter Kompetenztraining, 1030 Vienna, Austria; 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
2 TOTO Consulting LLC, Campbell, CA 95080, USA; 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
3 Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Schöpfstrasse 41/R311,6020 Innsbruck, Austria
*Correspondence: 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。; Tel.: +43-512-9003-70706
Abstract
The COVID-19 pandemic has inflicted unprecedented pressure on communities and health-care systems around the world. An outstandingly broad and intensive investigation of possible therapeutic interventions is currently taking place to prevent similar future threats to the global population. Investigating the related mechanisms of action is often complex and time consuming. Moreover, research on biochemical interactions of new drugs involves a considerable amount of effort, consequently bearing inherent financial and operational risks for pharmaceutical companies. An interesting approach to counteract colonization and infection is the concept of antiseptic treatment in vivo. Antiseptics are cost-effective and globally accessible, due to their ease of production, transportation and handling. A broad spectrum of active agents with different properties is readily available. One of these substances is hypochlorous acid (HOCl), which is also a naturally occurring biocidal agent and as such part of the innate immune system. Its successful history of medical use in wound treatment, combined with low cytotoxicity and documented efficacy against various pathogens, suggests that HOCl might be an effective agent for treating the respiratory mucosa. This could potentially enable therapeutic inhalation for combating bacterial infections and viral pathogens such as human respiratory syncytial, influenza, and SARS-CoV-2 viruses, which will be discussed in the present article.
Keywords: HOCl; respiratory infection; antiseptic; antimicrobial treatment; RSV; influenza; COVID-19; SARS-CoV-2
Ann Q. Tran, MD ; Nicole Topilow, MD; Andrew Rong, MD; Patrice J. Persad, PhD; Michael C. Lee; James H. Lee; Apostolos G. Anagnostopoulos, MD; and Wendy W. Lee, MD, MS
Background: Hypochlorous acid (HA) has both anti-microbial and wound-healing properties with a growing role for utilization in pre-procedural care on the face.
Objectives: The authors sought to compare the antiseptic property of 0.01% HA solution, 5% povidone iodine (PI), 4% chlorhexidine gluconate (CHG), and 70% isopropyl alcohol (IPA) antiseptic on facial skin.
Methods: This was a prospective single-center clinical trial.
Results: A total of 21 participants were recruited. Bacterial growth was seen in CHG (10%), IPA (71%), PI (81%), and HA (95%) of specimens (P < 0.001). CHG had less growth compared with HA (P = <0.001), IPA (P = <0.001), and PI (P = <0.001). No difference in bacterial growth was noted between HA and IPA (P = 0.063) or HA and PI (P = 0.25). Significant differences in mono-microbial and poly-microbial growth were seen between HA and IPA (P = 0.046) and HA and CHG (P = <0.001). Staphylococcus epidermidis grew less frequently in CHG (10%), followed by IPA (29%), PI (71%), and HA (71%). Staphylococcus capitis grew less frequently in CHG (0%), followed by PI (14%), HA (24%), and IPA (29%).
Conclusions: CHG reduced the bacterial growth compared with HA, PI, and IPA. However, HA, PI, and IPA had insignificant differences in bactericidal effects. Our study provides a supporting role of HA to be considered as an antiseptic.
创伤是指由于各种致伤因素导致的机体软组织、骨骼甚至内脏器官等等各个系统的损伤,创伤可以根据发生地点、受伤部位、受伤组织、致伤因素及皮肤完整程度进行分类。 按发生地点分为战争伤、工业伤、农业伤、交通伤、体育伤、生活伤等;按受伤部位分为颅脑创伤、胸部创伤、腹部创伤、各部位的骨折和关节脱位、手部伤等;按受伤类型分为骨折、脱位、脑震荡、器官破裂等;相邻部位同时受伤者称为联合伤(如胸腹联合伤);按受伤的组织或器官分类时,又可按受伤组织的深浅分为软组织创伤、骨关节创伤和内脏创伤。软组织创伤指皮肤、皮下组织和肌肉的损伤,也包括行于其中的血管和神经。单纯的软组织创伤一般较轻,但广泛的挤压伤可致挤压综合征。血管破裂大出血亦可致命。骨关节创伤包括骨折和脱位,并按受伤的骨或关节进一步分类并命名。如股骨骨折、肩关节脱位等。内脏创伤又可按受伤的具体内脏进行分类和命名。如脑挫裂伤、肺挫伤、肝破裂等。同一致伤原因引起两个以上部位或器官的创伤,称为多处伤或多发伤。按致伤因素,分为火器伤、切伤、刺伤、撕裂伤、挤压伤、扭伤、挫伤等。按皮肤完整程度,分为闭合性创伤、开放性创伤等。
伤口世界平台生态圈,以“关爱人间所有伤口患者”为愿景,连接、整合和拓展线上和线下的管理慢性伤口的资源,倡导远程、就近和居家管理慢性伤口,解决伤口专家的碎片化时间的价值创造、诊疗经验的裂变复制、和患者的就近、居家和低成本管理慢性伤口的问题。
2019广东省医疗行业协会伤口管理分会年会
扫一扫了解详情:
任何关于疾病的建议都不能替代执业医师的面对面诊断。所有门诊时间仅供参考,最终以医院当日公布为准。
网友、医生言论仅代表其个人观点,不代表本站同意其说法,请谨慎参阅,本站不承担由此引起的法律责任。